Financial Data and Key Metrics Changes - In Q2 2025, TV revenue grew over 35% to $67.8 million, with total revenue reaching $68.5 million, driven by customer acquisition and increased usage [7][16] - Gross margin improved to 77%, up from 70% in 2024, reflecting a 700 basis point increase [17] - Adjusted EBITDA grew 92% year over year to a record $14.5 million, with an adjusted EBITDA margin of 21% compared to 14% in 2024 [19][20] - The company ended the quarter with $175 million in cash and cash equivalents and no debt outstanding [20] Business Line Data and Key Metrics Changes - Performance TV revenue growth of 35% indicates strong customer adoption, particularly among small and medium-sized businesses [16] - The number of live customers on the platform increased by 85% year over year, with 97% of new customers having never advertised on TV before [9][10] Market Data and Key Metrics Changes - Nearly half of all TV time in the US is now streamed, yet only a third of TV ad budgets have followed, indicating a significant market opportunity for performance TV [9] - The company is targeting small and mid-sized businesses, which are increasingly recognizing the potential of TV advertising [95] Company Strategy and Development Direction - The company aims to democratize TV advertising, making it accessible and effective for brands of all sizes, particularly small and mid-sized businesses [5][6] - The strategy includes leveraging AI for targeting and creative processes to enhance customer acquisition and reduce costs [27][28] - The company is focused on maintaining operating leverage while investing in technology and development to drive future growth [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum and market opportunity, highlighting the shift towards performance TV as a viable growth channel [14][21] - The management noted that small and mid-sized businesses are expected to drive growth in TV advertising, similar to trends seen in job creation [96] Other Important Information - The company has a strong balance sheet with no debt and significant cash reserves, positioning it well for future investments [20] - The company is committed to strategic investments in R&D and go-to-market capabilities to support growth [21] Q&A Session Summary Question: Can you discuss the momentum you're seeing and what excites you most? - Management noted that small and mid-sized businesses are increasingly assuming they can use television for advertising, reflecting strong forward momentum [25][26] Question: How do you see margins trending and what are the key levers? - Management indicated a long-term gross margin target of 75% to 80%, with expectations for further improvements through reductions in hosting and media costs [30][31] Question: What impact has lowering the minimum spend had on the business? - The minimum spend per campaign has decreased from $25,000 to $500, allowing more small and medium-sized advertisers to access the platform [39] Question: Can you comment on net revenue retention rates? - While not quantified, management indicated that net retention rates are very strong, particularly among small businesses [45][46] Question: What is the growth outlook from the ZoomInfo deal? - The partnership with ZoomInfo is expected to drive advertisers to the platform, enhancing customer acquisition [51] Question: How is the go-to-market strategy evolving post-IPO? - The go-to-market strategy has become faster, leveraging AI tools for quicker customer onboarding [65] Question: Where is the biggest growth in new customers coming from? - Growth is seen in small franchises and local businesses, aided by the introduction of radius targeting [89] Question: How does the company define performance for its advertisers? - Over 80% of customers use return on ad spend as their key metric, with a focus on driving sales and conversions [76][85]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $326 million, representing a 41% increase year-over-year [6][39] - Royalty revenue grew 65% year-over-year to $206 million, driven by strong performance from established therapies [7][39] - Adjusted EBITDA increased 65% to $226 million compared to the prior year [7][39] - Full-year revenue guidance for 2025 was raised to $1.275 billion to $1.355 billion, reflecting 26% to 33% growth over 2024 [7][42] - Full-year royalty revenue guidance was increased to $825 million to $860 million, representing growth of 44% to 51% year-over-year [8][42] Business Line Data and Key Metrics Changes - The three established blockbuster therapies driving growth are Darzalex subcutaneous, FSGO, and Vyvgart Hytrulo [6][11] - Darzalex reported a revenue increase of almost 22% to $3.5 billion in the quarter, with a 96% conversion rate to subcutaneous delivery in the U.S. [13][16] - FSGO revenue for the first half of 2025 was approximately $1.5 billion, reflecting a 55% year-over-year growth [16][17] - Vyvgart Hytrulo sales increased 97% year-over-year to $949 million in the second quarter [18][39] Market Data and Key Metrics Changes - The global conversion rate for FSGO from Perjeta to FSGO was 46% across 78 launch countries [16][17] - Ocrevus revenue increased 8% to approximately $4.4 billion in 2025, with expectations for high single-digit growth [24][25] - Ribrovant subcutaneous revenue was $179 million, representing over 100% year-over-year growth [31][39] Company Strategy and Development Direction - The company is focusing on identifying new drug delivery platforms that can generate long-lasting revenue streams through royalties [9] - There is an emphasis on expanding the use of ENHANZE technology to enhance patient access and convenience [11][12] - The company is pursuing M&A opportunities while maintaining a disciplined approach to leverage [9][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of revenue streams and the potential for continued growth driven by multiple catalysts [44] - The company is actively engaging with regulatory bodies to ensure favorable outcomes regarding the IRA and CMS guidance [55][56] - Management remains optimistic about the ongoing performance of their blockbuster products and the potential for new product launches [44][66] Other Important Information - The company completed a $250 million share repurchase in the quarter and initiated a third tranche under a $750 million plan [9][37] - The company maintains a strong balance sheet with cash and marketable securities of $548 million as of June 30, 2025 [41] Q&A Session Summary Question: Status of IP litigation with Merck - The company is suing Merck for infringing 15 of its patents, with a scheduling order expected in the coming months [47][48] - Four PGRs filed by Merck have been scheduled for a hearing in March 2026, with decisions anticipated by June 2026 [49][50] Question: Confidence in regulatory front - Management is confident that there will be no impactful changes regarding the IRA and has submitted feedback to CMS [55][56] Question: Guidance setting process - The company uses trends and inputs from partners to set guidance, with updates occurring based on new data points [57][58] Question: Interest in high-volume auto injectors - There is strong interest from multiple companies in the high-volume auto injectors, with ongoing discussions at various stages [69][70] Question: Long-term guidance updates - The company updates long-term guidance annually, with more information expected at the start of the next year [66] Question: Impact of CMS guidance on deal conversations - The pending CMS guidance has not impacted deal conversations, as many companies are still interested in subcutaneous delivery options [88][89]

Financial Data and Key Metrics Changes - Jazz Pharmaceuticals reported total revenues of $1,050,000,000 for Q2 2025, representing a 2% increase year-over-year, driven by robust growth in Xywav, which grew 13% [31][32] - The adjusted net loss for Q2 2025 was $5,000,000, primarily due to a non-tax-deductible charge from the Chimerix acquisition [33] - Operating cash flow for the first half of the year was $519,000,000, with a strong balance sheet showing $1,700,000,000 in cash and investments at quarter-end [33][34] Business Line Data and Key Metrics Changes - In the neuroscience segment, Xywav generated approximately $415,000,000 in net product sales, with a 13% year-over-year increase [15][31] - Epidiolex saw net product sales of approximately $252,000,000, reflecting a 2% increase year-over-year, impacted by U.S. inventory dynamics [17][32] - Oncology products experienced a 1% decrease in total sales, primarily due to lower sales of Rylase and Zepzelca, offset by higher sales of ZYHERA, Defitelio, and Vyxeos [32] Market Data and Key Metrics Changes - The company noted strong underlying demand for Epidiolex, with expectations to reach blockbuster status this year despite inventory dynamics affecting growth rates [77][81] - Xywav remains the only low sodium oxybate therapy and the number one branded treatment for narcolepsy, with significant patient additions in both narcolepsy and idiopathic hypersomnia [10][15] - Zepzelca's net product sales were approximately $75,000,000, an 8% decrease year-over-year, attributed to increased competition and changes in treatment protocols [21][32] Company Strategy and Development Direction - The company is focused on executing its commercial strategy and advancing key development programs, with upcoming PDUFA dates for dorvaprone and Zepzelca [39][40] - Jazz Pharmaceuticals aims to leverage its diversified portfolio and robust pipeline for sustainable long-term growth, emphasizing the importance of capital allocation and corporate development [11][34] - The recent acquisition of Chimerix is expected to enhance Jazz's presence in rare oncology, particularly with the anticipated approval of dorvaprone [8][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the diversified portfolio and the potential for future growth, particularly with the upcoming FDA approvals [8][39] - The company acknowledged near-term headwinds in the oncology portfolio but remains optimistic about returning to growth driven by new opportunities [39] - Management emphasized the importance of execution and delivering innovative therapies for patients, with a focus on patient impact and corporate responsibility [11][39] Other Important Information - The company revised its financial guidance for 2025, narrowing the revenue range while adjusting SG&A and R&D guidance to enhance operational efficiency [34][35] - Jazz Pharmaceuticals is preparing for the commercial launch of dorvaprone and Zepzelca, with significant investments in marketing and education to support these products [34][36] Q&A Session Summary Question: What is driving the strength of Xywav and idiopathic hypersomnia? - Management highlighted strong execution across field teams, effective digital campaigns, and the role of field nurse educators in supporting patient persistence and education [42][46][47] Question: What can be expected from the ZANI Phase III trial? - Management indicated that top-line updates would focus on primary and significant secondary endpoints while preserving the ability to publish detailed results later [51][52] Question: What are the competitive headwinds for Zepzelca? - Management acknowledged increased competition and changes in treatment protocols affecting Zepzelca's sales but expressed optimism about upcoming approvals that could enhance its market position [57][61] Question: What underlies confidence in Epidiolex reaching blockbuster status? - Management cited strong underlying demand and anticipated inventory dynamics that would support growth, despite some fluctuations in quarterly comparisons [76][81] Question: How will the entry of multi-source generics impact the oxybate franchise? - Management emphasized the differentiation of Xywav as the only low sodium oxybate and its established position in the market, which should mitigate potential impacts from generics [78][79]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $165 million, a decrease from $168 million in the same quarter last year [17] - Net product sales were $158 million, with royalty, licensing, and other revenues at $7 million; excluding Trokendi XR and Oxtellar XR, total revenues increased by 17% compared to the same quarter last year [17] - GAAP net earnings were $22 million or $0.40 per diluted share, compared to $20 million or $0.36 per diluted share in the same quarter last year [18] - As of June 30, 2025, the company had approximately $523 million in cash, cash equivalents, and marketable securities, up from $454 million as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - KELBY experienced 31% growth in net sales and 23% growth in prescriptions, with approximately 36,000 prescribers, a 23% increase year-over-year [8][9] - GOCOVRI saw a 16% increase in net sales and a 14% increase in prescriptions, reaching approximately 1,900 prescribers [10] - ONAPCO launched successfully with over 750 patient enrollment forms submitted by more than 300 prescribers [11] - ZERZUVE reported Q2 2025 net revenues of $23.2 million, a 68% increase from $13.8 million in Q2 2024 [12] Market Data and Key Metrics Changes - KELBY's adult prescriptions grew by 29%, while pediatric prescriptions grew by 20% [30] - GOCOVRI's Medicare copay decreased significantly, with 97% of prescriptions having a copay of less than $25, down from 77% in 2024 [10] Company Strategy and Development Direction - The company is transitioning from legacy products to a new growth phase, focusing on KELBY, GOCOVRI, ONAPCO, and ZERZUVE as core growth drivers [7][70] - The acquisition of Sage Therapeutics is expected to accelerate mid to long-term revenue growth and cash flow [12] - Corporate development will prioritize revenue-generating products and opportunities in women's health, particularly in the OBGYN space [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting strong performance in the first half of 2025 and the positive impact of the Sage acquisition [22] - The company expects total revenues for 2025 to range from $670 million to $700 million, up from a previous range of $600 million to $630 million [22] - Operating loss for the full year 2025 is expected to be between $70 million and $80 million, primarily due to acquisition-related costs [23] Other Important Information - The company is on track to initiate a phase 2b trial for SPN-820 in adults with major depressive disorder [13] - The company completed a pharmacokinetic study for SPN-443, a new product candidate for ADHD and other CNS disorders [14] Q&A Session Summary Question: Pricing dynamics for KELBY and adult segment update - Management indicated that net pricing for KELBY remains above $300 per prescription, with adult prescriptions growing significantly [26][28] Question: Enrollment forms and sales for ONAPCO - Management reported over 750 enrollment forms submitted and approximately 200 patients currently receiving the product, with reimbursement processes going smoothly [27][32] Question: Sales growth for ZERZUVE - Management noted a 36% growth in prescriptions for ZERZUVE, attributing it to strong sales force expansion and investment [37][39] Question: KELBY launch initiatives and prescriber interest - Management highlighted the importance of new label changes and educational efforts for physicians, contributing to strong performance [45][46] Question: Future M&A focus and cash position post-Sage acquisition - Management confirmed a strong cash position of approximately $240 million to $260 million post-acquisition, with a focus on revenue-generating products in CNS and women's health [48][51]

Financial Data and Key Metrics Changes - Revenues grew by 9% year over year, with volume increasing by 13% [4][10] - Non-GAAP operating expenses rose by 8%, with non-GAAP R&D growth of 18% year over year [33] - Free cash flow generated in the second quarter was $1.9 billion, reflecting operational momentum [33] Business Line Data and Key Metrics Changes - General Medicine sales increased, with Repatha delivering $696 million, up 31% year over year [10][11] - EVENITY sales increased by 32% year over year to $518 million, with significant growth in the U.S. and Japan [11][12] - Rare disease portfolio grew by 19% year over year, delivering nearly $1.4 billion in sales [14] - Oncology portfolio generated $2.2 billion in sales, growing 14% year over year [18] - Biosimilars portfolio sales grew by 40% year over year to $661 million [20] Market Data and Key Metrics Changes - The U.S. market saw continued demand growth across cardiology and primary care [11] - Inflammation treatments showed strong adoption, with TestBio sales up 46% year over year [17] - The biosimilars market is evolving, with Amgen's portfolio generating nearly $12 billion in sales since 2018 [20][86] Company Strategy and Development Direction - The company is focused on innovation and expanding its pipeline, particularly in obesity, rare diseases, and oncology [6][8] - AI is seen as a key driver for enhancing innovation across the company [7][34] - The company aims to improve patient access and affordability while maintaining a commitment to innovation [5][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver innovation and growth in the long term [9][36] - The company anticipates total revenues for 2025 to be in the range of $35 billion to $36 billion [35] - Management acknowledged the need for reform in the U.S. healthcare system to improve medicine affordability [45][46] Other Important Information - The company is investing heavily in its late-stage pipeline, with a focus on Meritide and other key programs [34][36] - Capital expenditures for 2025 are expected to be $2.3 billion to expand network capacity [34] Q&A Session Summary Question: Granularity on Meritide data in Q4 - Management indicated that more data will be shared in due course regarding the phase two type two diabetes study and chronic weight management studies [41][42] Question: Thoughts on drug pricing reforms - Management emphasized the need for reform in the U.S. healthcare system and expressed a willingness to work with the administration to achieve objectives [44][46] Question: Appetite for M&A in rare diseases - Management remains interested in growing the rare disease business both organically and through potential acquisitions [49][50] Question: Design considerations for Meritide CVOT study - Management acknowledged the interest in the recent data from competitors and indicated that they are closely monitoring the situation [65][66] Question: Timeline for filing approval for bimetuzumab - Management has not disclosed the regulatory strategy yet but is excited about the positive results and their implications for patient treatment [70][71] Question: Confidence in the TestBiR COPD program - Management expressed strong confidence in the mechanism and the responder population for the TestBiR program [106][107] Question: Future of obesity treatments - Management is exploring opportunities to augment their offerings in obesity, including the potential for oral small molecules [111]

Financial Data and Key Metrics Changes - In Q2 2025, revenue reached $308 million, representing a 35% year-over-year increase, while adjusted EBITDA grew by 52% to $59 million, both exceeding guidance [6][14][20] - Free cash flow was $33.6 million, up 69% year-over-year, translating to a margin of 11% [20][26] - The company reported a GAAP net loss of $12.8 million, an improvement from a loss of $28.1 million in the previous year [20] Business Line Data and Key Metrics Changes - The total scaled customer count grew to 567, up 21% year-over-year, with 168 super scaled customers, an increase of 17% [17] - Quarterly ARPU for scaled customers was $532,000, an 11% increase year-over-year, while super scaled customer ARPU was $1.6 million, up 19% [17] - The agency business saw a 40% year-over-year increase in the average number of scaled brands per large agency holding company [18] Market Data and Key Metrics Changes - Six of the top ten verticals grew faster than 20% year-over-year, with technology and media, consumer and retail, and advertising and marketing being the largest contributors [18] - Direct revenue mix increased to 75%, up from 67% a year ago, resulting in direct revenue growth of 51% year-over-year [19] Company Strategy and Development Direction - The company is focused on AI innovation, launching Zeta Answers, a prescriptive AI framework that automates outcome-driven actions in real-time [7][9] - The One Zeta initiative aims to accelerate multi-use case adoption across acquisition, growth, and retention, leading to better ROI and customer stickiness [10][11] - The company is expanding its presence in the public sector, leveraging relationships built through its political business [92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in capturing more market share due to strong sales pipeline and AI-driven momentum [12][24] - The company raised its full-year revenue guidance by $21 million, reflecting strong first-half performance and customer behavior consistency [24][25] - Management remains committed to reducing equity dilution and achieving long-term targets, including over $2.1 billion in annual revenue by 2028 [27] Other Important Information - The company plans to host its fifth annual Zeta Live conference on October 9, featuring prominent speakers and a dedicated stage for product showcases [12][13] - A second Investor Day will be held on October 8 to share long-term roadmap and R&D pipeline [14] Q&A Session Summary Question: Interest level from customers regarding the new AI module - Management noted good awareness and meaningful uptake of the AI suite, with plans to showcase new products at Zeta Live [30][33] Question: Linearity in the quarter and growth consistency - Management confirmed consistent growth throughout the quarter, with strong performance across key verticals [34][35] Question: KPIs and sales productivity - Management highlighted strong sales productivity and pipeline conversion, with a focus on cost of revenue and expense management [42][44] Question: Trends in marketing operations and AI - Management indicated that most enterprises still rely on agencies for marketing, but many are testing AI tools internally [72] Question: Goals for the Zeta Data and AI Lab - The lab aims to drive innovation and stay ahead of competitors in AI tools and workflows [76] Question: Success with independent agencies - Management emphasized the importance of partnerships with independent agencies, providing them access to advanced AI tools [81][83] Question: Changes in customer behavior and pipeline filling - Management noted a shift in brand recognition, leading to a stronger pipeline and higher conversion rates [87]

Financial Data and Key Metrics Changes - Revenue for the second quarter reached $293 million, representing a 32% year-over-year increase [5][29] - Non-GAAP operating margin was 14%, with free cash flow of $59 million [29][33] - Non-GAAP gross margin was 76%, down approximately two points year-over-year due to increased infrastructure costs and SMS product growth [32][33] Business Line Data and Key Metrics Changes - The company ended the quarter with over 176,000 customers, a 17% year-over-year increase [30] - The number of customers with over $50,000 in ARR grew by 38% year-over-year, reaching 3,291 [31] - The marketing analytics product gained nearly 2,000 customers, demonstrating strong early adoption [30][16] Market Data and Key Metrics Changes - International revenue grew over 42% year-over-year, with notable growth in EMEA (47%) and APAC [31][24] - Specific countries like Norway, Germany, and Spain saw new ARR growth exceeding 90% year-over-year [92] Company Strategy and Development Direction - The company is focused on sustainable, efficient long-term growth, expanding internationally and moving upmarket [6][36] - Klaviyo aims to unify marketing, service, and analytics into a single platform, enhancing customer engagement and operational efficiency [8][17] - The introduction of AI-driven products is expected to enhance customer experiences and drive revenue growth [12][17] Management's Comments on Operating Environment and Future Outlook - Management noted that Klaviyo is more critical than ever for customers' growth, with no significant impact from the macroeconomic environment during the quarter [32][36] - The company is optimistic about future growth, raising full-year guidance based on strong first-half performance and customer demand [35][36] Other Important Information - The company announced leadership changes, including the appointment of a new Chief Information Officer and the retirement of the President [27][28] - Klaviyo is expanding its product offerings, including the launch of a help desk and conversational agents, which are currently in beta [12][47] Q&A Session Summary Question: Progress in the mid-market - Management highlighted strong unit economics and customer interest in the mid-market, with a focus on consolidating marketing and service [39][41] Question: Service suite opportunity sizing - Management believes the service suite could be as large as the marketing automation category, with significant interest from both SMBs and enterprises [47][49] Question: Gross margin dynamics - Management discussed the impact of SMS growth and infrastructure investments on gross margin, indicating a positive outlook for new products over time [68][70] Question: International growth and language rollout - International growth was strong, with ongoing language rollouts and improvements in product experience for global customers [92][94] Question: Evolving go-to-market strategy - The expansion of the product portfolio is leading to higher-level discussions with decision-makers beyond just marketing [80][82]

Financial Data and Key Metrics Changes - The company reported revenue of $965 million, exceeding the high end of guidance, with earnings per share of $1.33 and free cash flow of $253 million [5][14][17] - Gross profit was $454 million, resulting in gross margins of 47.1%, which was above expectations due to product mix and cost discipline [14][15] - Operating income reached $224 million, translating to an operating margin of 23.3% [15][16] - The effective tax rate was 11.2%, leading to a net income of $200 million [16] Business Line Data and Key Metrics Changes - Mobile revenue accounted for 62% of total revenue, up 1% sequentially and 8% year over year, driven by strong sell-through at the top customer and new Android product launches [14] - Broad markets, including Edge IoT, automotive, industrial, infrastructure, and cloud, grew 2% sequentially and 5% year over year, marking the sixth consecutive quarter of growth [14][10] Market Data and Key Metrics Changes - The automotive business is tracking around $60 million per quarter, significantly up year over year, with new programs secured with major OEMs [67] - The company noted that inventory levels are low, indicating a healthy demand environment across both mobile and non-mobile segments [70] Company Strategy and Development Direction - The company is focusing on long-term RF content growth driven by internal modem adoption, higher RF complexity with AI features, and a larger addressable footprint within smartphones [6][8] - A planned closure of the Woburn manufacturing facility aims to optimize manufacturing footprint, drive higher fab utilization, and improve overall efficiency [10][11] - The company is committed to maintaining a disciplined approach to operating expenses while investing in R&D initiatives [18][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong demand signals and healthy sell-through, particularly in mobile, while actively monitoring inventory levels [5][6] - The company anticipates revenue for the next quarter to range between $1 billion to $1.03 billion, with expectations of mid-single-digit sequential growth in mobile [18] - Management highlighted the importance of diversification beyond the handset market to mitigate risks associated with customer concentration [44] Other Important Information - The company returned $430 million to shareholders during the quarter, including $104 million in dividends and $330 million in share repurchases [17] - The company ended the quarter with $1.3 billion in cash and investments, maintaining a strong balance sheet [17] Q&A Session Summary Question: Changes in handset business over the last ninety days - Management noted strong demand for products, particularly from the largest customer, which reflects in their results and guidance [22][23] Question: December seasonality and impact of the extra week - Management indicated solid demand across mobile and non-mobile, with low inventories, making it difficult to predict December seasonality [24][25][26] Question: Internal modem impact on blended content - Management acknowledged that more content is available with the internal modem, but the overall impact will depend on customer shipping decisions [30][34] Question: Automotive business size and growth potential - The automotive business is currently around $60 million per quarter and is expected to grow significantly due to long design cycles and new programs [67] Question: Operating expenses outlook - Management emphasized a disciplined approach to operating expenses, with modest increases targeted at core R&D initiatives [72] Question: Infrastructure networking cloud segment performance - Management confirmed that inventory issues in the infrastructure segment appear to be resolved, with demand aligning with consumption [77]

Financial Data and Key Metrics Changes - Total revenue for Q2 was approximately $257 million, up 102% year-on-year, including fee revenue of approximately $241 million, which was up 84% year-on-year [28][30] - GAAP net income for Q2 was approximately positive $6 million, ahead of expectations, marking a return to profitability a quarter earlier than anticipated [31] - Adjusted EBITDA was $53 million, reflecting strong operating leverage [31] - Average loan size was approximately $7,570, which was 15% lower than the prior quarter due to model advancements driving higher approval rates for smaller loan amounts [29] Business Line Data and Key Metrics Changes - Originations on the Upstart platform in Q2 reached $2.8 billion, the highest volume in three years [9] - The auto business grew 87% sequentially, while the home business grew 67% sequentially [9] - More than 10% of originations came from newer businesses, including small dollar loans, which grew 40% sequentially [9][12] Market Data and Key Metrics Changes - The Upstart Macro Index has been largely stable for several months, indicating no significant macro improvements or Fed rate decreases impacting growth [10] - The volume of loan transactions across the platform was approximately 373,000, up 159% from the prior year [29] Company Strategy and Development Direction - The company aims for market share leadership in home and auto lending, with significant investments in these areas expected to yield fast growth and strong credit performance [17] - The strategy includes transitioning most funding for newer products off the balance sheet by 2025 [12][33] - The company is focused on creating a differentiated experience in home and auto lending, leveraging AI to reduce origination costs and improve consumer experience [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth of the core personal loan business, despite the scaling of new products [27] - The macro environment is expected to remain steady, with no significant changes anticipated in interest rates or labor market conditions [34] - The company plans to continue launching model enhancements to improve conversion rates and maintain robust take rates and contribution margins [34] Other Important Information - The company has made significant advancements in AI technology, with Model 22 improving separation accuracy by 17 percentage points [18] - Year-over-year population-adjusted delinquency rates are down 20%, and raw delinquency rates are down 32% due to servicing optimizations [20] Q&A Session Summary Question: Discussion on ABS market and competitive pressure - Management noted that the ABS market is constructive, but the equity tranche market is opportunistic with buyers picking and choosing deals [39] - Increased competition is expected as funding markets improve, but the company remains focused on maintaining strong offers and growing market share [40] Question: Transition to external funding and balance sheet impact - Management indicated a timeline for transitioning to external funding between now and the end of the year, with expectations for the balance sheet to start releasing as new flows are secured [44] Question: Contribution margin improvement - The contribution margin improved due to a mix benefit from more core borrower segment loans and improved take rates driven by model enhancements [52] Question: Macro assumptions and guidance - Management expects a steady macro environment with no significant changes in interest rates or default rates, planning conservatively for the remainder of the year [55] Question: Average loan size and strategic shifts - The decrease in average loan size is strategic, reflecting rapid growth in the small dollar product, which is intended to increase the number of users on the platform [67] Question: Funding partners for new products - The company plans to secure a combination of bank and credit union partners for home and auto products, leveraging their familiarity with these offerings [77] Question: Conversion rate improvement and Walmart partnership - Management did not provide specific forecasts for conversion rates but noted that the Walmart partnership continues to be successful [82]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 increased by 21% year over year to $189 million, surpassing the raised guidance [6][24] - Adjusted EBITDA grew by 22% year over year to $57 million, with a margin of 30%, up from 27% in Q1 2025 [24][29] - Media transactions measured (NTMs) increased by 19% year over year, while measured transaction fees (NTS) declined by 1% year over year, indicating a relative improvement [25][51] Business Line Data and Key Metrics Changes - Activation revenue grew by 25% year over year, with all four activation solution groupings contributing to growth [25] - Social measurement revenue rose by 14%, driven by platforms like YouTube, TikTok, and Meta, which collectively accounted for over 90% of Q2 social measurement revenue [27][12] - Supply side revenue increased by 26% year over year, reflecting growth from existing and new platform and publisher customers [28] Market Data and Key Metrics Changes - CTV measurement impressions grew by 45% year over year, representing 11% of total measurement impression volumes [15] - Social media remains a significant growth opportunity, with social measurement revenue growth led by major platforms [11][12] - Programmatic volume saw healthy growth, with ABS (Authentic Brand Suitability) growing by 23% year over year [19][48] Company Strategy and Development Direction - The company is focused on expanding relationships with existing advertisers and scaling new ones, emphasizing a strategy of "attach, stack, and scale" [7][10] - The recently launched Media Advantage Platform (MAP) integrates verification, optimization, and outcomes measurement, enhancing customer engagement [8][22] - The company aims to leverage AI innovations and expand its product suite to navigate a shifting market [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory, supported by strong enterprise win rates and an active pipeline [22][33] - The company raised its full-year 2025 revenue growth guidance to approximately 15% year over year, up from 13% [32] - Management noted that 2025 is viewed as a transition year, with gradual monetization expected from new solutions like Meta Prescreen and DV Authentic Advantage [34] Other Important Information - The company ended the quarter with approximately $217 million in cash and cash equivalents, maintaining a strong financial position [31][34] - Capital expenditures were approximately $10 million, reflecting ongoing investments in cloud infrastructure and product development [30][29] Q&A Session Summary Question: What drove the acceleration in social growth? - Management indicated that growth was driven by both new user expansion and existing customers increasing their usage, alongside the addition of new partners [38][40] Question: Can you elaborate on the drivers of outperformance relative to guidance? - The strong activation quarter, particularly around ABS, was highlighted as a key driver of growth, alongside resilient advertiser spending despite macro uncertainties [46][48] Question: How confident is the company in the sustainability of social product growth? - Management expressed increased confidence due to improvements in product offerings and the ability to provide both pre- and post-bid solutions [56][58] Question: What is the outlook for margins moving forward? - The company is guiding for a 32% EBITDA margin for the year, with continued investments in growth initiatives [91][92] Question: How is the company approaching capital allocation? - The strategy remains balanced between investments in the business, evaluating M&A opportunities, and considering share repurchases [82][84]